Amplia Therapeutics Limited
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develo… Read more
Amplia Therapeutics Limited (INNMF) - Net Assets
Latest net assets as of September 2025: $42.93 Million USD
Based on the latest financial reports, Amplia Therapeutics Limited (INNMF) has net assets worth $42.93 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($44.54 Million) and total liabilities ($1.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $42.93 Million |
| % of Total Assets | 96.38% |
| Annual Growth Rate | 8.75% |
| 5-Year Change | 103.34% |
| 10-Year Change | 425.19% |
| Growth Volatility | 99.71 |
Amplia Therapeutics Limited - Net Assets Trend (2010–2025)
This chart illustrates how Amplia Therapeutics Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Amplia Therapeutics Limited (2010–2025)
The table below shows the annual net assets of Amplia Therapeutics Limited from 2010 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $21.02 Million | +84.13% |
| 2024-03-31 | $11.42 Million | -27.89% |
| 2023-03-31 | $15.84 Million | -27.52% |
| 2022-03-31 | $21.85 Million | +111.29% |
| 2021-03-31 | $10.34 Million | +20.15% |
| 2020-03-31 | $8.61 Million | -0.68% |
| 2019-03-31 | $8.66 Million | +266.48% |
| 2018-03-31 | $2.36 Million | -64.33% |
| 2017-03-31 | $6.63 Million | +65.59% |
| 2016-03-31 | $4.00 Million | -17.73% |
| 2015-03-31 | $4.87 Million | -50.21% |
| 2014-03-31 | $9.77 Million | -13.02% |
| 2013-03-31 | $11.23 Million | +251.66% |
| 2012-03-31 | $3.19 Million | -47.41% |
| 2011-03-31 | $6.07 Million | +1.61% |
| 2010-03-31 | $5.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amplia Therapeutics Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5686647600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $167.39 Million | 796.15% |
| Other Comprehensive Income | $-826.19K | -3.93% |
| Total Equity | $21.02 Million | 100.00% |
Amplia Therapeutics Limited Competitors by Market Cap
The table below lists competitors of Amplia Therapeutics Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PT Sinar Eka Selaras Tbk
JK:ERAL
|
$20.60 Million |
|
Yong Shun Chemical Co Ltd
TWO:4711
|
$20.60 Million |
|
iMBC Co.Ltd
KQ:052220
|
$20.60 Million |
|
Hank Payments Corp.
PINK:HNKPF
|
$20.60 Million |
|
Aesler Grup Internasional Tbk Pt
JK:RONY
|
$20.59 Million |
|
BG Container Glass Public Company Limited
BK:BGC
|
$20.59 Million |
|
Bizim Toptan Satis Magazalari AS
IS:BIZIM
|
$20.58 Million |
|
HEALTH NET
F:HNT
|
$20.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amplia Therapeutics Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,418,309 to 21,024,950, a change of 9,606,641 (84.1%).
- Net loss of 6,572,031 reduced equity.
- Share repurchases of 1,330,243 reduced equity.
- New share issuances of 17,280,909 increased equity.
- Other comprehensive income increased equity by 270,346.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.57 Million | -31.26% |
| Share Repurchases | $1.33 Million | -6.33% |
| Share Issuances | $17.28 Million | +82.19% |
| Other Comprehensive Income | $270.35K | +1.29% |
| Other Changes | $-42.34K | -0.2% |
| Total Change | $- | 84.13% |
Book Value vs Market Value Analysis
This analysis compares Amplia Therapeutics Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.69x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.17x to 0.69x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-03-31 | $0.28 | $0.05 | x |
| 2011-03-31 | $0.29 | $0.05 | x |
| 2012-03-31 | $0.15 | $0.05 | x |
| 2013-03-31 | $0.65 | $0.05 | x |
| 2014-03-31 | $0.75 | $0.05 | x |
| 2015-03-31 | $0.26 | $0.05 | x |
| 2016-03-31 | $0.19 | $0.05 | x |
| 2017-03-31 | $0.28 | $0.05 | x |
| 2018-03-31 | $0.09 | $0.05 | x |
| 2019-03-31 | $0.20 | $0.05 | x |
| 2020-03-31 | $0.16 | $0.05 | x |
| 2021-03-31 | $0.11 | $0.05 | x |
| 2022-03-31 | $0.15 | $0.05 | x |
| 2023-03-31 | $0.08 | $0.05 | x |
| 2024-03-31 | $0.06 | $0.05 | x |
| 2025-03-31 | $0.07 | $0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amplia Therapeutics Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -173.69%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.09x
- Recent ROE (-31.26%) is above the historical average (-62.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -67.99% | 0.00% | 0.00x | 1.37x | $-4.66 Million |
| 2011 | -40.21% | 0.00% | 0.00x | 1.29x | $-3.05 Million |
| 2012 | -101.84% | 0.00% | 0.00x | 1.80x | $-3.57 Million |
| 2013 | -30.16% | 0.00% | 0.00x | 1.02x | $-4.51 Million |
| 2014 | -46.00% | 0.00% | 0.00x | 1.04x | $-5.47 Million |
| 2015 | -107.62% | -17278.70% | 0.01x | 1.09x | $-5.72 Million |
| 2016 | -123.48% | -218.40% | 0.45x | 1.26x | $-5.34 Million |
| 2017 | -106.75% | -393.54% | 0.24x | 1.14x | $-7.74 Million |
| 2018 | -181.77% | -740.59% | 0.22x | 1.12x | $-4.53 Million |
| 2019 | -21.58% | -3704.79% | 0.01x | 1.06x | $-2.74 Million |
| 2020 | -25.79% | -6484.57% | 0.00x | 1.06x | $-3.08 Million |
| 2021 | -22.06% | -148.75% | 0.14x | 1.05x | $-3.32 Million |
| 2022 | -16.68% | -183.74% | 0.08x | 1.12x | $-5.83 Million |
| 2023 | -39.42% | -524.80% | 0.06x | 1.18x | $-7.83 Million |
| 2024 | -39.44% | -101.14% | 0.30x | 1.30x | $-5.65 Million |
| 2025 | -31.26% | -173.69% | 0.16x | 1.09x | $-8.67 Million |
Industry Comparison
This section compares Amplia Therapeutics Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amplia Therapeutics Limited (INNMF) | $42.93 Million | -67.99% | 0.04x | $20.60 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |